Medicine composition used for treating myocardial ischemia and preparation method thereof

Abstract

The invention discloses a medicine composition used for treating myocardial ischemia and a preparation method thereof. The medicine composition used for treating myocardial ischemia is prepared from, by weight, 1.2-3.5 parts of bishydroxycoumarin, 1.0-3.0 parts of beta-ecdysterone, 0.8-4.2 parts of betulin, 1.2-3.6 parts of myristic acid, 0.2-0.8 part of bergapten, 0.1-0.5 part of anti-thrombotic medicine, 0.1-0.2 part of naltrexone, 0.3-1.0 part of menthol, 1.2-2.0 parts of kaempferol-3-rhamnoglucoside, 0.5-2.0 parts of phycocyanobilin, 0.2-0.5 part of erythropoietin, 0.1-1.0 part of alginic acid, 0.1-0.6 part of panaxoside, 0.1-0.2 part of catechinic acid, 0.3-1.2 parts of timnodonic acid and 3.0-10 parts of Arab galactose. The medicine composition used for treating myocardial ischemia is safe, effective, easy to prepare and free of toxic or side effect, can lower myocardial oxygen consumption, relieve myocardial metabolic disorder and correct hemodynamics disorder, has the remarkable effect on treating myocardial ischemia, and has the practical application value clinically for treating or preventing myocardial ischemia.

Description

technical field [0001] The invention relates to the technical field of cardiovascular disease medication, in particular to a pharmaceutical composition for protecting myocardial ischemia and a preparation method thereof. Background technique [0002] Cardiovascular and cerebrovascular diseases are collectively referred to as cardiovascular and cerebrovascular diseases, and generally refer to ischemic or hemorrhagic diseases in the heart, brain, and systemic tissues caused by hyperlipidemia, blood viscosity, atherosclerosis, and high blood pressure. . It is a common disease that seriously threatens the health of human beings, especially middle-aged and elderly people over 50 years old. Even with the most advanced and perfect treatment methods, more than 50% of the survivors of cerebrovascular accidents still cannot take care of themselves completely. The number of people dying from cardiovascular and cerebrovascular diseases is as high as 15 million every year, ranking first...

AI Technical Summary

Problems solved by technology

[0006] With the development of modern medicine, myocardial ischemia has achieved rapid development in prevention, diagnosis, and treatment. However, due to its many complications and complex mechanisms, coupled with the limitations of therapeutic drugs, it has brought certain difficulties to the prevention and treatment work.

In the prior art, the simple use of drugs such as nitrates, calcium channel blockers or beta receptor blockers has a significant effect on the treatment of myocardial ischemia, and plays an important role in prolonging the life of patients and improving the quality of life of patients. These drugs also have limitations, for example, nitrates are prone to tolerance, calcium channel blockers can cause reflexive sympathetic stimulation, and beta receptor blockers have adverse effects on blood lipids and blood sugar